Aptamers Which Bind to a Target Molecule Involved in Haemostasis

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel aptamers—short strands of DNA or RNA—that specifically bind to molecules involved in blood clotting (haemostasis), particularly activated protein C (APC) and thrombin. The aptamers exhibit high affinity and specificity for their targets, making them effective for detecting, quantifying, or inhibiting these proteins. The patent covers both single aptamers for APC and fusion aptamers capable of binding thrombin (with linkers connecting multiple aptamer units), allowing them to serve as diagnostic agents, therapeutic agents, or anticoagulants.

Use CasesContent extracted from patent full text and abstract with AI.

• Diagnostic tests to measure activated protein C levels in blood (for coagulation disorders or sepsis diagnostics).
• Therapeutic agents to modulate blood clotting in patients with haemostasis disorders such as hemophilia, thrombosis, or excessive bleeding.
• Antidotes for recombinant APC therapy to prevent or stop bleeding complications caused by overdosage.
• Manufacturing of purification kits for APC or thrombin from blood or plasma samples (affinity chromatography).
• Development of advanced anticoagulant drugs (especially fusion aptamers) for use in surgeries, extracorporeal circulation (dialysis, heart-lung machines), or treatment of thrombosis and embolism.
• Research tools for investigating the molecular mechanisms of haemostasis and APC/thrombin function.

BenefitsContent extracted from patent full text and abstract with AI.

• High specificity and affinity for activated protein C and thrombin, enabling accurate detection or inhibition even in the presence of similar proteins.
• Allows for rapid, reliable, and cost-effective diagnostic tests compared to antibody-based methods.
• Synthetic production of aptamers ensures consistency, scalability, and lower risk of immune reactions compared to antibodies.
• Fusion aptamers offer stronger or multifunctional inhibition of thrombin, potentially superior to single aptamers or currently available anticoagulants.
• Aptamer effects can be reversed by administration of complementary sequences, offering controllable therapeutic outcomes.
• Chemical modifications enhance aptamer stability in biological fluids, making them suitable for in vivo and in vitro applications.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to an aptamer which binds to a target molecule involved in haemostasis, where the aptamer is an aptamer which binds to activated protein C, where the aptamer binds to activated protein C with a dissociation constant KD in the range from = 0.001 nM to = 80 nM, and where the aptamer has a length in the range from = 20 nucleotides to = 160 nucleotides, or where the aptamer is a thrombin-binding fusion aptamer comprising at least two aptamers which bind to thrombin and at least one linker, where the at least one linker connects the at least two aptamers which bind to thrombin.